TY - JOUR AU - Takeuchi, Akihiko AU - Tsuchiya, Hiroyuki AU - Ishii, Takeshi AU - Nishida, Yoshihiro AU - Abe, Satoshi AU - Matsumine, Akihiko AU - Kawai, Akira AU - Yoshimura, Kenichi AU - Ueda, Takafumi PY - 2016 DA - 2016/07/22 TI - Clinical outcome of recurrent giant cell tumor of the extremity in the era before molecular target therapy: the Japanese Musculoskeletal Oncology Group study JO - BMC Musculoskeletal Disorders SP - 306 VL - 17 IS - 1 AB - Giant cell tumor of the bone (GCTB) is classified as an intermediate, locally aggressive but rarely metastasizing tumor. The mainstay of treatment for the treatment of GCTB had been the surgical removal until an anti- receptor activator of nuclear factor-kappa B ligands (RANKL) antibody denosumab was developed. And favorable responses and the possibility of surgical downstaging have been reported. However, the long-term outcome of denosumab has not yet been confirmed and moreover the long-term clinical outcome after the recurrence of GCTB in the era before molecular target therapy is still uncertain. The aim of this study was to evaluate the long-term clinical outcome of recurrent GCTB of the extremity in the era before molecular target therapy and to determine the factors that affect the repetitive recurrence and sacrifice of adjacent joints. SN - 1471-2474 UR - https://doi.org/10.1186/s12891-016-1163-z DO - 10.1186/s12891-016-1163-z ID - Takeuchi2016 ER -